Pfizer's Reviral deal a potential boost for LianBio - Jefferies

LianBio

07/04/2022 15:02

** Brokerage Jefferies says Pfizer's buyout of LianBio
 LIAN.O  partner ReViral suggests drugmaker has confidence in
companies' RSV drug 
    ** Pfizer Inc  PFE.N  buys LIAN's partner ReViral Ltd in
deal worth as much as $525 mln, gaining access to treatments for
respiratory syncytial virus (RSV)  urn:newsml:reuters.com:*:nL3N2W526H
    ** LIAN owns China rights for one of ReViral's RSV drugs 
    ** This deal obviously speaks to some confidence PFE has in
ongoing Phase II RSV studies, and should increase investor
confidence in LIAN's RSV program - Jefferies  
     ** U.S.-listed ADRs of China-based LIAN flat at $4.96 after
rising as much as 1.4%
    ** LIAN shares have fallen in recent weeks, along with other
China stocks, over fears of being delisted; stock down nearly
20% YTD 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))